Scholarlink

Background <p>In this study, we compared the incidence of short-term outcomes between two groups of patients based on the occurrence of intra-procedural slow-flow/no-reflow phenomenon (SF/NR) and identified predictors of short-term outcomes. This study enrolled a&#xa0;consecutive series of patients diagnosed with ST-elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (PCI).</p> Methods <p>The patients were divided into two groups based on the presence or absence of SF/NR, and the incidence of short-term major adverse cardiovascular events (MACE) was compared between the two groups. Furthermore, the study aimed to identify predictors of short-term mortality in these patients. A&#xa0;total of 2582 patients were included, of whom 79.1% (<i>n</i>=2042) were male.</p> Results <p>The average age of the patients was 55.7 ± 11.2&#xa0;years. Intra-procedural SF/NR was observed in 21.7% (560) of the patients. During median short-term follow-up of 180&#xa0;days (144–205), patients with SF/NR exhibited a&#xa0;higher incidence of all-cause mortality (23.6% vs. 12.3%; <i>p</i> &lt; 0.001) and MACE (30.4% vs. 16.9%; <i>p</i> &lt; 0.001), with a&#xa0;hazard ratio of 1.82 (1.46–2.27; <i>p</i> &lt; 0.001) and 1.69 (1.39–2.05; <i>p</i> &lt; 0.001), respectively. Among patients with SF/NR, the following were found to be independent predictors of short-term mortality (adjusted odds ratios): total ischemic time, 1.04 (1.00–1.07; <i>p</i> = 0.041); random blood sugar levels, 1.01 (1.00–1.01; <i>p</i> &lt; 0.001); intubation status, 2.79 (1.26–6.18; <i>p</i> = 0.011); post-procedural sub-optimal flow, 1.76 (1.04–2.98; <i>p</i> = 0.034); and intra-procedural arrhythmias, 5.48 (2.03–14.79; <i>p</i> &lt; 0.001).</p> Conclusion <p>The presence of intra-procedural SF/NR has significant prognostic implications. Patients with intra-procedural SF/NR face a&#xa0;significantly higher risk of short-term adverse outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prognosticating short-term outcomes in patients with STEMI-ACS and intra-procedural slow-flow/no-reflow phenomenon

  • 期刊论文

  • 发表日期：

    2025年8月14日

查看全文
  • Rajesh Kumar,
  • Abdul Hakeem Shaikh,
  • Ayaz Mir,
  • Uroosa Safdar,
  • Ishrat Fatima,
  • Mahesh Kumar Batra,
  • Musa Karim

摘要

Background

In this study, we compared the incidence of short-term outcomes between two groups of patients based on the occurrence of intra-procedural slow-flow/no-reflow phenomenon (SF/NR) and identified predictors of short-term outcomes. This study enrolled a consecutive series of patients diagnosed with ST-elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (PCI).

Methods

The patients were divided into two groups based on the presence or absence of SF/NR, and the incidence of short-term major adverse cardiovascular events (MACE) was compared between the two groups. Furthermore, the study aimed to identify predictors of short-term mortality in these patients. A total of 2582 patients were included, of whom 79.1% (n=2042) were male.

Results

The average age of the patients was 55.7 ± 11.2 years. Intra-procedural SF/NR was observed in 21.7% (560) of the patients. During median short-term follow-up of 180 days (144–205), patients with SF/NR exhibited a higher incidence of all-cause mortality (23.6% vs. 12.3%; p < 0.001) and MACE (30.4% vs. 16.9%; p < 0.001), with a hazard ratio of 1.82 (1.46–2.27; p < 0.001) and 1.69 (1.39–2.05; p < 0.001), respectively. Among patients with SF/NR, the following were found to be independent predictors of short-term mortality (adjusted odds ratios): total ischemic time, 1.04 (1.00–1.07; p = 0.041); random blood sugar levels, 1.01 (1.00–1.01; p < 0.001); intubation status, 2.79 (1.26–6.18; p = 0.011); post-procedural sub-optimal flow, 1.76 (1.04–2.98; p = 0.034); and intra-procedural arrhythmias, 5.48 (2.03–14.79; p < 0.001).

Conclusion

The presence of intra-procedural SF/NR has significant prognostic implications. Patients with intra-procedural SF/NR face a significantly higher risk of short-term adverse outcomes.